k141_68388_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	37.9	549	580	575	1.03e-112	347
k141_68388_2	SARG|gb|AAK76137.1|ARO:3000024|patA	34.9	570	580	564	1.49e-97	307
k141_68388_2	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.2	563	580	582	1.17e-62	215
k141_68388_2	SARG|gb|AAK76136.1|ARO:3000025|patB	27.5	530	580	588	5.62e-54	192
k141_68388_2	SARG|gi|739906046|ref|WP_037756452.1|	27.7	538	580	620	2.31e-52	188
k141_68388_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.1	487	580	664	5.40e-51	185
k141_68388_2	SARG|gi|516574297|ref|WP_017949361.1|	27.5	538	580	620	5.64e-51	184
k141_68388_2	SARG|gi|917229923|ref|WP_051836635.1|	28.4	559	580	620	1.47e-50	183
k141_68388_2	SARG|gi|648667297|ref|WP_026359044.1|	27.7	581	580	605	3.08e-50	182
k141_68388_2	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	26.9	591	580	579	5.42e-50	181
k141_68388_3	SARG|gi|944009777|ref|WP_055601444.1|	34.1	575	586	628	2.80e-95	303
k141_68388_3	SARG|gi|944152509|ref|WP_055644808.1|	33.9	575	586	616	1.13e-94	301
k141_68388_3	SARG|gb|AYV52072.1|ARO:3002882|lmrD	36.4	516	586	664	2.62e-94	301
k141_68388_3	SARG|gb|AAK76136.1|ARO:3000025|patB	33.7	555	586	588	3.00e-94	299
k141_68388_3	SARG|gi|947982677|ref|WP_056642336.1|	33.6	575	586	626	8.43e-93	296
k141_68388_3	SARG|gi|639892676|ref|WP_024755698.1|	33.6	575	586	631	9.54e-93	296
k141_68388_3	SARG|gi|926376632|ref|WP_053705806.1|	33.3	579	586	620	2.14e-91	293
k141_68388_3	SARG|gi|1033217078|gb|OAR27197.1|	32.8	576	586	601	1.02e-90	290
k141_68388_3	SARG|gi|860594225|ref|WP_048475168.1|	33.4	574	586	620	1.16e-90	291
k141_68388_3	SARG|gi|497748188|ref|WP_010062372.1|	32.5	573	586	605	1.58e-90	290
k141_68388_5	NCBI|WP_139847607.1|1|1|erm(53)|erm(53)|target_modification|2|MACROLIDE|MACROLIDE|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(53)|AMR|macrolide	29.6	186	288	300	1.53e-19	85.5
k141_68388_5	SARG|P43433	31.0	187	288	311	3.32e-16	76.3
k141_68388_5	SARG|AAA22075	30.0	190	288	340	9.06e-15	72.4
k141_68388_5	SARG|L22689.1.gene1.p01	28.8	139	288	257	6.81e-10	57.4
k141_68388_5	SARG|gb|OPG86592.1|ARO:3004626|Erm(49)	24.7	190	288	304	2.37e-08	53.1
k141_110230_1	SARG|gi|498115003|ref|WP_010429159.1|	49.1	232	261	646	4.40e-68	221
k141_110230_1	SARG|gi|896106549|ref|WP_049136608.1|	49.1	232	261	646	1.21e-67	219
k141_110230_1	SARG|gi|654544841|ref|WP_028012549.1|	48.7	232	261	646	1.69e-67	219
k141_110230_1	SARG|gi|782756348|ref|WP_045630015.1|	49.1	232	261	646	2.36e-67	219
k141_110230_1	SARG|gi|829942568|ref|WP_047368199.1|	48.7	232	261	646	2.36e-67	219
k141_110230_1	SARG|gi|1022698495|ref|WP_063449190.1|	49.1	232	261	646	3.30e-67	218
k141_110230_1	SARG|gi|754493745|ref|WP_041910640.1|	48.7	232	261	646	3.30e-67	218
k141_110230_1	SARG|gi|895898290|ref|WP_048999361.1|	48.7	232	261	646	4.62e-67	218
k141_110230_1	SARG|gi|1028112073|ref|WP_063866263.1|	49.1	232	261	646	4.62e-67	218
k141_110230_1	SARG|gi|969848384|ref|WP_058609247.1|	48.7	232	261	646	6.46e-67	218
k141_110230_2	SARG|gi|1001720867|ref|WP_061274204.1|	31.0	429	429	648	5.58e-34	133
k141_110230_2	SARG|gb|AAV85982.1|ARO:3000535|macB	30.9	430	429	644	7.42e-34	132
k141_110230_2	SARG|gi|495736522|ref|WP_008461101.1|	30.8	429	429	648	1.39e-33	132
k141_110230_2	SARG|gi|746243059|ref|WP_039291473.1|	30.8	429	429	648	1.39e-33	132
k141_110230_2	SARG|gi|746253210|ref|WP_039301529.1|	30.8	429	429	648	1.39e-33	132
k141_110230_2	SARG|gi|736472622|ref|WP_034494292.1|	30.3	429	429	648	1.58e-32	129
k141_110230_2	SARG|gi|1035706844|ref|WP_064548272.1|	30.8	429	429	648	1.58e-32	129
k141_110230_2	SARG|gi|1035670474|ref|WP_064517458.1|	30.5	429	429	648	2.90e-32	128
k141_110230_2	SARG|gi|1035717981|ref|WP_064557480.1|	30.5	429	429	648	2.90e-32	128
k141_110230_2	SARG|gi|495067432|ref|WP_007792257.1|	30.2	434	429	647	9.71e-32	126
k141_110230_3	SARG|gb|AML99881.1|ARO:3001327|mdtK	27.6	413	419	474	1.46e-40	149
k141_125477_5	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	22.2	856	848	1024	1.79e-23	105
k141_125477_5	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.2	856	848	1024	1.79e-23	105
k141_125477_5	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.0	747	848	1024	2.36e-23	105
k141_125477_5	SARG|gb|CAA53189|ARO:3000521|mupA	23.0	747	848	1024	2.36e-23	105
k141_167305_7	SARG|gi|556476567|ref|WP_023328168.1|	34.8	184	467	641	6.51e-21	94.7
k141_167305_7	SARG|gi|1033064422|ref|WP_064375412.1|	36.0	189	467	648	1.56e-20	93.6
k141_167305_7	SARG|gi|647265102|ref|WP_025712979.1|	33.9	192	467	646	4.91e-20	92.0
k141_167305_7	SARG|gi|895899849|ref|WP_049000782.1|	33.9	192	467	646	6.54e-20	91.7
k141_167305_7	SARG|gi|895903124|ref|WP_049003730.1|	33.9	189	467	646	8.71e-20	91.3
k141_167305_7	SARG|gi|695793471|ref|WP_032707680.1|	34.4	189	467	648	8.74e-20	91.3
k141_167305_7	SARG|gi|823291602|ref|WP_047047573.1|	33.9	189	467	648	8.74e-20	91.3
k141_167305_7	SARG|gi|823302270|ref|WP_047057473.1|	34.4	189	467	648	8.74e-20	91.3
k141_167305_7	SARG|gi|976146774|ref|WP_059305359.1|	34.4	189	467	648	8.74e-20	91.3
k141_167305_7	SARG|gi|1022664304|ref|WP_063420886.1|	34.4	189	467	648	8.74e-20	91.3
k141_72478_3	SARG|gi|764446018|ref|WP_044369325.1|	24.9	233	503	605	1.27e-07	53.1
k141_72478_3	SARG|gi|695865802|ref|WP_032778631.1|	24.9	233	503	605	1.27e-07	53.1
k141_72478_3	SARG|gb|AAK76137.1|ARO:3000024|patA	24.5	241	503	564	1.62e-07	52.8
k141_72478_3	SARG|gi|951183771|ref|WP_057661487.1|	25.2	234	503	603	1.67e-07	52.8
k141_72478_3	SARG|gi|827013130|ref|WP_047175495.1|	24.8	234	503	603	1.67e-07	52.8
k141_72478_3	SARG|gi|695891735|ref|WP_032792824.1|	24.8	234	503	603	1.67e-07	52.8
k141_72478_3	SARG|gi|664042835|ref|WP_030582300.1|	25.2	234	503	604	1.68e-07	52.8
k141_72478_3	SARG|gi|695887424|ref|WP_032788534.1|	24.9	233	503	605	1.68e-07	52.8
k141_72478_3	SARG|gi|664180077|ref|WP_030714054.1|	24.9	233	503	605	1.68e-07	52.8
k141_72478_3	SARG|gi|913055317|ref|WP_050357634.1|	24.8	234	503	603	2.21e-07	52.4
k141_72478_7	SARG|gb|AAC75314.1|ARO:3003578|pmrF	25.2	313	329	322	3.46e-27	107
k141_72478_11	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	23.8	189	188	574	2.32e-07	48.9
k141_72478_11	SARG|gi|951389844|ref|WP_057765492.1|	25.7	148	188	492	1.35e-06	46.6
k141_72478_11	SARG|gi|445983951|ref|WP_000061806.1|	25.0	148	188	492	1.82e-06	46.2
k141_72478_11	ResF|poxtA-Ef_1_WP094899500.1_1	25.4	189	188	538	3.39e-06	45.4
k141_72478_11	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	25.4	189	188	543	3.40e-06	45.4
k141_72478_11	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	25.4	189	188	543	3.40e-06	45.4
k141_72478_11	SARG|gi|738272573|ref|WP_036227195.1|	24.3	148	188	492	4.47e-06	45.1
k141_72478_11	SARG|gi|651595894|ref|WP_026590859.1|	26.2	149	188	492	6.03e-06	44.7
k141_72478_11	SARG|gi|983301550|ref|WP_060487860.1|	26.7	120	188	492	8.14e-06	44.3
k141_72478_11	SARG|gi|640690880|ref|WP_025115215.1|	26.7	120	188	492	8.14e-06	44.3
k141_76145_10	SARG|gb|CAE00499.1|ARO:3003835|cdeA	35.4	435	449	441	2.05e-92	285
k141_57307_1	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	38.0	387	366	533	2.21e-66	218
k141_57307_1	SARG|AF353562.gene.p01	36.5	375	366	369	7.42e-61	199
k141_11817_4	SARG|gb|APB03219.1|ARO:3003986|TaeA	34.2	374	364	648	4.40e-56	192
k141_11817_4	SARG|AAA50325	32.9	389	364	569	1.37e-49	174
k141_11817_4	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	368	364	655	2.92e-48	171
k141_11817_4	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	368	364	655	4.03e-48	171
k141_11817_4	SARG|gb|AKA86814|ARO:3003746|optrA	31.0	368	364	655	4.03e-48	171
k141_11817_4	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	368	364	655	2.02e-47	169
k141_11817_4	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	368	364	655	2.02e-47	169
k141_11817_4	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	368	364	655	2.02e-47	169
k141_11817_4	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	368	364	655	2.79e-47	169
k141_11817_4	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	368	364	655	2.79e-47	169
k141_19517_4	SARG|gb|AAC75314.1|ARO:3003578|pmrF	32.6	95	330	322	1.12e-06	48.5
k141_141030_2	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_4	33.8	237	270	247	1.87e-40	139
k141_141030_2	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_4	32.5	237	270	246	5.09e-40	138
k141_141030_2	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_3	34.0	238	270	248	2.29e-38	134
k141_141030_2	megares|MEG_7537|Drugs|Glycopeptide|VanA-type_accessory_protein|VANWA_1	31.6	234	270	271	2.40e-36	129
k141_141030_2	NCBI|WP_063856764.1|1|1|vanW-Pt|vanW-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-Pt|AMR|glycopeptide	31.6	234	270	271	2.40e-36	129
k141_141030_2	NCBI|WP_002368694.1|1|1|vanW-B|vanW-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-B|AMR|glycopeptide	28.8	229	270	275	4.49e-33	120
k141_141030_2	NCBI|WP_032489744.1|1|1|vanW-B|vanW-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-B|AMR|glycopeptide	28.8	229	270	275	6.64e-32	117
k141_141030_2	NCBI|WP_010815683.1|1|1|vanW-B|vanW-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-B|AMR|glycopeptide	27.9	229	270	275	1.30e-31	117
k141_141030_2	NCBI|WP_063856765.1|1|1|vanW-B|vanW-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-B|AMR|glycopeptide	27.9	229	270	275	2.55e-31	116
k141_141030_2	NCBI|WP_063856763.1|1|1|vanW-B|vanW-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-B|AMR|glycopeptide	27.5	229	270	275	9.77e-31	114
k141_42268_3	SARG|gb|AAA26793|ARO:3003748|oleC	29.0	210	426	325	1.48e-22	96.7
k141_42268_3	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	29.0	210	426	325	1.48e-22	96.7
k141_42268_3	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	27.7	206	426	255	1.82e-16	77.8
k141_42268_3	SARG|gb|AAR96051.1|ARO:3002894|otrC	26.5	211	426	351	3.38e-14	72.4
k141_42268_3	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	26.1	211	426	351	1.95e-13	70.1
k141_122093_3	SARG|gi|498424272|ref|WP_010730861.1|	24.7	223	253	498	3.27e-07	49.7
k141_122093_3	SARG|gi|498524203|ref|WP_010823919.1|	24.7	235	253	498	4.38e-07	49.3
k141_122093_3	SARG|gi|498393490|ref|WP_010707193.1|	24.7	235	253	498	4.38e-07	49.3
k141_122093_3	SARG|gi|498399943|ref|WP_010713140.1|	24.7	235	253	498	4.38e-07	49.3
k141_122093_3	SARG|gi|488338532|ref|WP_002407917.1|	24.7	223	253	498	4.38e-07	49.3
k141_122093_3	SARG|gi|488303094|ref|WP_002374069.1|	24.7	235	253	498	4.38e-07	49.3
k141_122093_3	SARG|gi|514908720|ref|WP_016633351.1|	24.7	235	253	498	4.38e-07	49.3
k141_122093_3	SARG|gi|895819918|ref|WP_048943810.1|	24.7	235	253	498	5.86e-07	48.9
k141_122093_3	SARG|gi|498528849|ref|WP_010828356.1|	24.7	235	253	498	5.86e-07	48.9
k141_122093_3	SARG|gi|488324747|ref|WP_002394132.1|	24.7	235	253	498	5.86e-07	48.9
k141_15743_10	CARD|gb|WKR28567.1|ARO:3007678|IreK	30.5	154	550	718	5.76e-09	57.8
k141_91848_2	SARG|gi|445996709|ref|WP_000074564.1|	35.2	213	287	309	5.74e-30	114
k141_91848_2	SARG|gi|445996710|ref|WP_000074565.1|	35.3	215	287	309	1.55e-29	112
k141_91848_2	SARG|gi|542061059|gb|ERI11611.1|	33.8	213	287	316	3.42e-29	112
k141_91848_2	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	32.9	216	287	307	5.63e-29	111
k141_91848_2	SARG|gi|814314593|emb|CKF49145.1|	34.7	213	287	309	8.13e-29	110
k141_91848_2	SARG|gi|895736250|emb|COF64653.1|	34.7	213	287	309	1.13e-28	110
k141_91848_2	SARG|gi|446110087|ref|WP_000187942.1|	34.7	213	287	309	1.13e-28	110
k141_91848_2	SARG|gi|445996714|ref|WP_000074569.1|	34.7	213	287	309	1.57e-28	110
k141_91848_2	SARG|gi|500465078|gb|EOP76697.1|	35.8	204	287	306	2.07e-28	109
k141_91848_2	SARG|gi|500448961|gb|EOP61695.1|	35.8	204	287	306	2.89e-28	109
k141_91848_4	SARG|gb|AAK76137.1|ARO:3000024|patA	26.6	241	240	564	2.51e-13	67.8
k141_91848_5	SARG|gb|AAA26793|ARO:3003748|oleC	28.6	231	254	325	6.50e-23	94.4
k141_91848_5	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	28.8	222	254	325	9.00e-23	94.0
k141_91848_5	SARG|gb|AAC75271.1|ARO:3003952|yojI	26.9	212	254	547	1.17e-17	80.9
k141_91848_5	SARG|gb|CDO61516.1|ARO:3003949|efrB	27.3	165	254	362	1.59e-11	62.4
k141_137489_8	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	29.9	690	660	703	4.91e-81	270
k141_141258_1	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.4	121	467	229	7.46e-15	72.8
k141_141258_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.5	104	467	231	1.91e-14	71.6
k141_141258_1	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	28.9	152	467	231	2.15e-13	68.6
k141_141258_1	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.6	152	467	231	2.91e-13	68.2
k141_141258_1	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	28.9	152	467	231	7.18e-13	67.0
k141_141258_1	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	28.9	152	467	231	9.71e-13	66.6
k141_141258_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.7	104	467	232	1.09e-11	63.5
k141_141258_1	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	33.9	127	467	232	6.60e-11	61.2
k141_141258_1	CARD|gb|ADM92605.1|ARO:3000553|adeR	32.8	116	467	247	1.44e-10	60.5
k141_141258_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.7	107	467	228	2.07e-10	59.7
k141_145014_4	SARG|gi|446110301|ref|WP_000188156.1|	42.1	214	249	648	1.50e-39	143
k141_145014_4	SARG|gi|446110287|ref|WP_000188142.1|	41.7	216	249	648	2.06e-39	143
k141_145014_4	SARG|gi|545167026|ref|WP_021521592.1|	41.6	214	249	648	3.89e-39	142
k141_145014_4	SARG|gi|446110295|ref|WP_000188150.1|	41.6	214	249	648	3.89e-39	142
k141_145014_4	SARG|gi|693106883|ref|WP_032260279.1|	41.6	214	249	648	5.34e-39	142
k141_145014_4	SARG|gi|446110272|ref|WP_000188127.1|	41.6	214	249	648	5.34e-39	142
k141_145014_4	SARG|gi|391288090|gb|EIQ46599.1|	41.6	214	249	645	7.21e-39	141
k141_145014_4	SARG|gi|754697027|ref|WP_042073841.1|	41.6	214	249	648	7.34e-39	141
k141_145014_4	SARG|gi|446110279|ref|WP_000188134.1|	41.6	214	249	648	7.34e-39	141
k141_145014_4	SARG|gi|1015927937|ref|WP_062886781.1|	41.6	214	249	648	7.34e-39	141
k141_145014_7	SARG|gb|AAK76136.1|ARO:3000025|patB	37.3	584	619	588	7.40e-107	333
k141_145014_7	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.2	543	619	664	9.05e-94	301
k141_145014_7	SARG|gi|944152509|ref|WP_055644808.1|	33.3	618	619	616	6.59e-91	292
k141_145014_7	SARG|gi|947982677|ref|WP_056642336.1|	33.0	618	619	626	4.81e-89	288
k141_145014_7	SARG|gi|639892676|ref|WP_024755698.1|	32.8	618	619	631	1.49e-88	286
k141_145014_7	SARG|gi|944009777|ref|WP_055601444.1|	32.6	616	619	628	2.04e-87	283
k141_145014_7	SARG|gi|558888514|ref|WP_023543283.1|	32.8	612	619	615	2.93e-87	283
k141_145014_7	SARG|AF170880.4.gene1.p01	32.8	612	619	615	4.11e-87	282
k141_145014_7	SARG|gi|1033217078|gb|OAR27197.1|	32.4	612	619	601	5.73e-87	281
k141_145014_7	SARG|gi|663330365|ref|WP_030329892.1|	32.6	626	619	607	1.30e-86	281
k141_145014_8	SARG|gb|WP_104671188.1|ARO:3003948|efrA	35.3	569	584	575	1.22e-115	354
k141_145014_8	SARG|gb|AAK76137.1|ARO:3000024|patA	35.5	518	584	564	1.81e-96	304
k141_145014_8	SARG|gi|748767925|ref|WP_040019608.1|	31.9	587	584	623	2.28e-77	256
k141_145014_8	SARG|AF170880.4.gene1.p01	33.1	580	584	615	7.27e-77	254
k141_145014_8	SARG|gi|943896259|ref|WP_055534530.1|	33.0	582	584	601	7.43e-77	254
k141_145014_8	SARG|gi|664556405|ref|WP_031071225.1|	32.4	592	584	602	7.60e-77	254
k141_145014_8	SARG|gi|517347347|ref|WP_018522839.1|	33.3	582	584	601	1.04e-76	253
k141_145014_8	SARG|gi|860594225|ref|WP_048475168.1|	32.8	576	584	620	3.08e-76	253
k141_145014_8	SARG|gi|917166849|ref|WP_051773561.1|	32.8	576	584	620	3.08e-76	253
k141_145014_8	SARG|gi|505420018|ref|WP_015607120.1|	33.0	572	584	603	5.78e-76	251
k141_175558_1	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	28.2	418	387	633	2.23e-24	103
k141_126169_3	SARG|YP_348488	25.0	848	1488	1043	5.13e-46	180
k141_126169_3	NCBI|AAN29241.1|1|1|bepE|bepE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepE|AMR|efflux	25.1	789	1488	1051	1.92e-44	175
k141_126169_3	ResF|tmexD4_1_CP091084_1	24.0	845	1488	1044	1.30e-43	172
k141_126169_3	NCBI|WP_027591160.1|1|1|tmexD2|tmexD|efflux|2|TIGECYCLINE|TETRACYCLINE|multidrug_efflux_RND_transporter_permease_subunit_TMexD2|AMR|tetracycline	24.1	845	1488	1044	2.26e-43	171
k141_126169_3	NCBI|WP_063865404.1|1|1|oqxB10|oqxB|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_OqxB10|AMR|multidrug	25.1	825	1488	1050	1.20e-42	169
k141_126169_3	NCBI|WP_063865418.1|1|1|oqxB13|oqxB|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_OqxB13|AMR|multidrug	25.2	825	1488	1050	1.20e-42	169
k141_126169_3	CARD|gb|AAL14440.1|ARO:3000775|adeB	23.3	806	1488	1035	2.01e-42	168
k141_126169_3	SARG|gi|852273548|ref|WP_048328542.1|	24.9	857	1488	1043	2.05e-42	168
k141_126169_3	NCBI|WP_021312368.1|1|1|oqxB20|oqxB|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_OqxB20|AMR|multidrug	25.0	825	1488	1050	2.08e-42	168
k141_126169_3	NCBI|WP_004149399.1|1|1|oqxB19|oqxB|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_OqxB19|AMR|multidrug	25.0	825	1488	1050	2.08e-42	168
k141_141483_1	NCBI|WP_070509550.1|1|1|mef(H)|mef(H)|efflux|2|ERYTHROMYCIN|MACROLIDE|macrolide_efflux_MFS_transporter_Mef(H)|AMR|macrolide	45.9	122	128	412	1.19e-28	106
k141_141483_2	NCBI|ACF30254.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	39.6	48	212	210	4.86e-06	44.7
k141_141483_2	NCBI|CAA81047.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	39.6	48	212	210	4.86e-06	44.7
k141_141483_5	SARG|ZP_04081918	26.5	223	233	306	2.06e-20	86.7
k141_141483_5	SARG|gi|446026113|ref|WP_000103968.1|	25.2	222	233	306	2.06e-20	86.7
k141_141483_5	SARG|gi|447195836|ref|WP_001273092.1|	25.9	224	233	306	2.06e-20	86.7
k141_141483_5	SARG|gi|447195835|ref|WP_001273091.1|	25.9	224	233	306	2.85e-20	86.3
k141_141483_5	SARG|gi|507044560|ref|WP_016115614.1|	24.8	222	233	306	1.44e-19	84.3
k141_141483_5	SARG|gi|500465078|gb|EOP76697.1|	24.3	222	233	306	1.44e-19	84.3
k141_141483_5	SARG|gi|445996722|ref|WP_000074577.1|	23.8	223	233	309	1.49e-19	84.3
k141_141483_5	SARG|gi|500448961|gb|EOP61695.1|	24.3	222	233	306	1.99e-19	84.0
k141_141483_5	SARG|P42332	24.6	224	233	306	1.99e-19	84.0
k141_141483_5	SARG|ABB80128	24.6	224	233	306	1.99e-19	84.0
k141_168171_3	megares|MEG_727|Drugs|beta-lactam|Class_C_betalactamases|AMPC_1	35.9	409	412	415	7.33e-91	279
k141_92312_7	SARG|gi|445996719|ref|WP_000074574.1|	41.8	213	338	309	2.43e-46	158
k141_92312_7	SARG|gi|542061059|gb|ERI11611.1|	42.5	221	338	316	4.07e-46	158
k141_92312_7	SARG|gi|447195835|ref|WP_001273091.1|	42.3	213	338	306	1.73e-45	156
k141_92312_7	SARG|gi|445996710|ref|WP_000074565.1|	40.3	221	338	309	2.61e-45	155
k141_92312_7	SARG|gi|445996723|ref|WP_000074578.1|	41.3	213	338	309	3.67e-45	155
k141_92312_7	SARG|ZP_04081918	41.8	213	338	306	4.78e-45	155
k141_92312_7	SARG|gi|447195836|ref|WP_001273092.1|	41.8	213	338	306	4.78e-45	155
k141_92312_7	SARG|gi|447057509|ref|WP_001134765.1|	40.8	213	338	309	5.15e-45	155
k141_92312_7	SARG|gi|445996722|ref|WP_000074577.1|	40.8	213	338	309	5.15e-45	155
k141_92312_7	SARG|gi|1043490477|ref|WP_065382463.1|	40.8	213	338	309	1.01e-44	154
k141_111058_3	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	29.1	223	683	359	2.99e-19	89.0
k141_111058_3	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	26.3	240	683	364	1.02e-18	87.4
k141_111058_3	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	26.3	240	683	364	1.02e-18	87.4
k141_111058_3	CARD|gb|AEX49906.1|ARO:3003583|basS	25.9	243	683	477	6.89e-15	76.6
k141_111058_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	30.6	121	683	232	3.34e-11	62.8
k141_111058_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	27.3	121	683	231	6.54e-10	58.9
k141_111058_5	SARG|gb|ABA71733.1|ARO:3002972|vanTG	37.0	370	394	712	1.31e-67	226
k141_111058_5	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	35.2	375	394	712	2.53e-58	201
k141_111058_5	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	33.2	370	394	711	7.43e-52	183
k141_111058_5	SARG|JF802084.2.gene3.p01	32.2	342	394	700	9.23e-47	169
k141_111058_5	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	31.0	368	394	366	3.89e-45	158
k141_111058_5	megares|MEG_7535|Drugs|Glycopeptide|VanN-type_resistance_protein|VANTN_1	33.3	270	394	656	1.60e-34	134
k141_111058_6	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.1	436	603	629	2.38e-26	112
k141_111058_6	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.1	436	603	629	2.38e-26	112
k141_111058_6	ResF|tet(O/W)_3_AM889120_1	26.1	436	603	639	2.47e-26	112
k141_111058_6	ResF|tet(O/W)_4_AM889121_1	26.1	436	603	639	2.47e-26	112
k141_111058_6	SARG|gi|1004359922|gb|AMP42228.1|	25.9	441	603	639	4.37e-26	112
k141_111058_6	SARG|AAO42740	25.9	436	603	639	4.37e-26	112
k141_111058_6	SARG|AY485126.gene.p01	25.9	436	603	639	4.37e-26	112
k141_111058_6	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.9	436	603	639	4.37e-26	112
k141_111058_6	SARG|ACI02041	26.7	439	603	639	4.37e-26	112
k141_111058_6	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.1	436	603	629	7.49e-26	111
k141_133869_17	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	35.7	224	250	255	5.52e-35	124
k141_133869_17	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	27.6	210	250	528	2.77e-10	58.9
k141_172259_4	SARG|gi|1008988570|ref|WP_061884457.1|	29.1	206	247	492	2.19e-12	65.1
k141_172259_4	SARG|gi|765018624|ref|WP_044584737.1|	28.6	206	247	492	3.98e-12	64.3
k141_172259_4	SARG|gi|445983935|ref|WP_000061790.1|	28.6	206	247	492	3.98e-12	64.3
k141_172259_4	SARG|gi|445983943|ref|WP_000061798.1|	28.6	206	247	492	3.98e-12	64.3
k141_172259_4	SARG|gi|1005558399|ref|WP_061655514.1|	28.6	206	247	492	3.98e-12	64.3
k141_172259_4	SARG|gi|445983944|ref|WP_000061799.1|	28.6	206	247	492	3.98e-12	64.3
k141_172259_4	SARG|gi|651595894|ref|WP_026590859.1|	28.2	206	247	492	7.22e-12	63.5
k141_172259_4	SARG|gi|445983919|ref|WP_000061774.1|	28.2	206	247	492	7.22e-12	63.5
k141_172259_4	SARG|gi|822524709|ref|WP_046954623.1|	28.2	206	247	492	7.22e-12	63.5
k141_172259_4	SARG|gi|516130021|ref|WP_017560601.1|	27.7	206	247	492	9.73e-12	63.2
k141_5110_1	SARG|gb|AAC75314.1|ARO:3003578|pmrF	31.0	271	275	322	3.68e-39	138
k141_5110_6	CARD|gb|AAC75429.1|ARO:3000833|evgS	31.9	382	944	1197	9.21e-46	177
k141_5110_6	CARD|gb|AEX49906.1|ARO:3003583|basS	24.5	253	944	477	4.20e-18	87.4
k141_5110_6	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.1	112	944	228	3.81e-13	68.9
k141_5110_6	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.3	127	944	232	4.51e-12	65.9
k141_5110_6	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	31.6	117	944	231	8.10e-12	65.1
k141_5110_6	CARD|gb|ATC67679.1|ARO:3000838|arlR	33.1	118	944	219	1.65e-11	63.9
k141_5110_6	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.5	124	944	219	2.22e-11	63.5
k141_5110_6	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.5	124	944	219	2.22e-11	63.5
k141_5110_6	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.5	124	944	220	2.26e-11	63.5
k141_5110_6	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.5	124	944	220	4.13e-11	62.8
k141_81282_1	SARG|gi|921231571|ref|WP_053176464.1|	24.1	526	529	620	7.81e-32	128
k141_81282_1	SARG|gi|926356413|ref|WP_053687351.1|	25.0	488	529	620	7.81e-32	128
k141_81282_1	SARG|gi|926294973|ref|WP_053631154.1|	25.0	488	529	620	7.81e-32	128
k141_81282_1	SARG|gi|917172177|ref|WP_051778889.1|	24.1	526	529	620	1.05e-31	128
k141_81282_1	SARG|gi|919568551|ref|WP_052871170.1|	24.0	526	529	620	1.05e-31	128
k141_81282_1	SARG|gi|772774655|ref|WP_045322518.1|	25.0	488	529	620	1.05e-31	128
k141_81282_1	SARG|gi|928900436|ref|WP_053931243.1|	24.6	488	529	600	1.27e-31	127
k141_81282_1	SARG|gi|664579989|ref|WP_031094015.1|	24.6	488	529	601	1.27e-31	127
k141_81282_1	SARG|gi|1045390184|ref|WP_065479071.1|	24.0	479	529	605	1.30e-31	127
k141_81282_1	SARG|gi|764446018|ref|WP_044369325.1|	24.0	479	529	605	3.19e-31	126
k141_81282_2	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	28.3	449	547	579	2.32e-46	170
k141_81282_2	SARG|AF170880.4.gene1.p01	29.1	477	547	615	2.72e-46	170
k141_81282_2	SARG|gi|558888514|ref|WP_023543283.1|	28.9	477	547	615	9.61e-46	169
k141_81282_2	SARG|gi|860594225|ref|WP_048475168.1|	31.0	455	547	620	1.02e-45	169
k141_81282_2	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	28.3	449	547	579	1.56e-45	167
k141_81282_2	SARG|gi|926400371|ref|WP_053728483.1|	30.2	527	547	603	1.42e-44	165
k141_81282_2	SARG|gi|496018010|ref|WP_008742581.1|	31.7	463	547	623	3.35e-44	164
k141_81282_2	SARG|gi|663350985|ref|WP_030349761.1|	29.3	457	547	613	6.85e-43	160
k141_81282_2	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	23.7	443	547	574	1.35e-24	106
k141_157197_2	SARG|gi|664556405|ref|WP_031071225.1|	34.8	589	591	602	2.69e-93	297
k141_157197_2	SARG|gi|517787730|ref|WP_018957938.1|	34.2	591	591	610	3.53e-92	295
k141_157197_2	SARG|gi|664395661|ref|WP_030922045.1|	34.3	594	591	601	7.77e-92	293
k141_157197_2	SARG|gi|860594225|ref|WP_048475168.1|	33.7	590	591	620	8.90e-92	294
k141_157197_2	SARG|gi|664458452|ref|WP_030980047.1|	34.3	594	591	601	3.01e-91	292
k141_157197_2	SARG|gi|695887424|ref|WP_032788534.1|	33.2	581	591	605	3.33e-91	292
k141_157197_2	SARG|gi|928900436|ref|WP_053931243.1|	33.7	585	591	600	4.12e-91	291
k141_157197_2	SARG|gi|664579989|ref|WP_031094015.1|	33.7	585	591	601	4.22e-91	291
k141_157197_2	SARG|gi|663330365|ref|WP_030329892.1|	33.5	570	591	607	6.88e-91	291
k141_157197_2	SARG|gi|947982677|ref|WP_056642336.1|	34.3	597	591	626	7.84e-91	291
k141_54733_6	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	38.9	90	102	228	4.80e-16	69.3
k141_54733_9	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	30.4	217	417	361	3.89e-17	81.3
k141_54733_9	megares|MEG_7499|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.4	217	417	361	3.89e-17	81.3
k141_54733_9	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.7	212	417	352	2.15e-16	79.0
k141_54733_9	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.0	217	417	361	2.31e-16	79.0
k141_54733_9	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	30.0	217	417	361	2.31e-16	79.0
k141_54733_9	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.7	212	417	376	2.57e-16	79.0
k141_54733_9	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	30.7	212	417	376	2.57e-16	79.0
k141_54733_9	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	27.1	207	417	392	7.11e-15	74.7
k141_54733_9	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.9	214	417	354	7.56e-15	74.3
k141_54733_9	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.9	214	417	354	1.01e-14	73.9
k141_54733_10	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	39.6	217	218	228	3.66e-46	151
k141_54733_10	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	37.7	223	218	231	7.10e-44	145
k141_54733_10	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.7	223	218	232	2.90e-43	144
k141_54733_10	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.9	217	218	219	4.49e-39	133
k141_54733_10	CARD|gb|AAG06465.1|ARO:3005063|cprR	34.1	217	218	223	3.95e-38	130
k141_54733_10	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.2	213	218	219	7.06e-38	130
k141_54733_10	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.2	213	218	219	9.97e-38	129
k141_54733_10	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.2	213	218	220	1.02e-37	129
k141_54733_10	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.2	213	218	220	2.04e-37	129
k141_54733_10	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.4	227	218	231	3.83e-37	128
k141_54733_11	SARG|L42544.gene.p01	29.9	648	872	651	2.76e-77	263
k141_54733_11	SARG|AAV80410	29.9	648	872	651	3.82e-77	263
k141_54733_11	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	29.4	622	872	641	2.08e-75	258
k141_54733_11	SARG|AAZ79478	29.4	622	872	657	2.92e-75	258
k141_54733_11	SARG|Q00937	29.6	622	872	641	9.57e-73	250
k141_54733_11	SARG|ZP_04557016	29.6	622	872	657	1.33e-72	250
k141_54733_11	SARG|Q08425	29.1	622	872	641	2.51e-72	249
k141_54733_11	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	29.2	623	872	654	3.29e-72	249
k141_54733_11	SARG|Q52360	29.3	622	872	641	3.47e-72	249
k141_54733_11	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	29.1	622	872	657	3.49e-72	249
k141_73713_1	SARG|NP_348076	28.0	411	432	652	1.26e-38	146
k141_73713_1	SARG|YP_002850805	28.2	411	432	652	3.80e-37	142
k141_73713_1	SARG|L20800.gene.p01	27.6	417	432	652	9.59e-37	141
k141_73713_1	SARG|ZP_02952732	27.7	411	432	652	1.78e-36	140
k141_73713_1	SARG|ZP_02632674	27.7	411	432	660	1.86e-36	140
k141_73713_1	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	28.8	385	432	654	1.73e-29	120
k141_73713_1	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	28.8	385	432	670	1.80e-29	120
k141_73713_1	SARG|AAB51122	28.8	385	432	670	1.80e-29	120
k141_73713_1	SARG|Q08425	28.8	385	432	641	3.03e-29	119
k141_73713_1	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	28.8	385	432	657	3.17e-29	119
k141_12756_2	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	41.1	158	162	159	5.31e-37	124
k141_130800_2	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	25.8	267	672	1033	6.85e-09	58.2
k141_130800_2	SARG|gb|AEY83581|ARO:3000510|mupB	25.8	267	672	1033	6.85e-09	58.2
k141_130800_2	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	30.3	132	672	1024	2.13e-06	50.1
k141_130800_2	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	30.3	132	672	1024	2.13e-06	50.1
k141_130800_2	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	30.3	132	672	1024	2.13e-06	50.1
k141_130800_2	SARG|gb|CAA53189|ARO:3000521|mupA	30.3	132	672	1024	2.13e-06	50.1
k141_100510_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.1	229	221	231	1.11e-43	145
k141_100510_2	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.1	229	221	231	1.11e-43	145
k141_100510_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.3	229	221	232	6.39e-43	143
k141_100510_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.3	229	221	232	6.39e-43	143
k141_100510_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.2	224	221	219	8.89e-43	142
k141_100510_2	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.4	229	221	231	3.89e-41	139
k141_100510_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.4	229	221	231	1.09e-40	137
k141_100510_2	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.3	236	221	231	8.64e-40	135
k141_100510_2	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.9	217	221	219	8.82e-40	135
k141_100510_2	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.9	217	221	219	2.48e-39	134
k141_100510_3	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.0	227	401	370	4.61e-12	65.9
k141_100510_3	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	23.3	227	401	365	1.44e-10	61.2
k141_100510_3	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.3	191	401	367	1.94e-10	60.8
k141_100510_3	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.3	191	401	368	1.94e-10	60.8
k141_100510_3	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	26.1	207	401	386	3.68e-10	60.1
k141_100510_3	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	26.1	207	401	386	3.68e-10	60.1
k141_100510_3	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	26.1	207	401	388	4.92e-10	59.7
k141_100510_3	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	26.1	207	401	388	4.92e-10	59.7
k141_100510_3	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	26.6	192	401	392	6.64e-10	59.3
k141_100510_3	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	25.1	207	401	386	8.67e-10	58.9
k141_58503_3	SARG|NP_348076	24.3	671	691	652	2.72e-46	173
k141_58503_3	SARG|ZP_02952732	24.5	674	691	652	3.70e-46	173
k141_58503_3	SARG|ZP_02632674	24.5	674	691	660	4.04e-46	173
k141_58503_3	SARG|L20800.gene.p01	24.5	674	691	652	6.82e-46	172
k141_58503_3	SARG|YP_002850805	24.5	674	691	652	9.27e-46	172
k141_58503_3	SARG|AAV80410	22.6	663	691	651	5.48e-43	164
k141_58503_3	SARG|gi|254621976|gb|ACT76130.1|	23.9	673	691	639	6.56e-43	163
k141_58503_3	SARG|L42544.gene.p01	22.5	663	691	651	7.42e-43	163
k141_58503_3	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	24.1	673	691	639	1.63e-42	162
k141_58503_3	SARG|gi|254621974|gb|ACT76129.1|	23.9	673	691	639	1.63e-42	162
k141_176640_4	SARG|gi|446573718|ref|WP_000651064.1|	22.5	432	452	451	4.63e-18	85.1
k141_176640_4	SARG|gi|505177635|ref|WP_015364737.1|	22.9	433	452	451	1.11e-17	84.0
k141_176640_4	SARG|gi|686155635|ref|WP_031787393.1|	22.5	432	452	451	1.48e-17	83.6
k141_176640_4	SARG|ZP_04679156	21.9	433	452	451	4.76e-16	79.0
k141_176640_4	SARG|HE999704.1.gene3064.p01	30.9	178	452	241	1.39e-15	75.1
k141_176640_4	SARG|gi|686309068|ref|WP_031870147.1|	22.0	432	452	451	3.56e-15	76.3
k141_176640_4	SARG|gi|686320684|ref|WP_031875798.1|	21.8	432	452	451	4.75e-15	75.9
k141_176640_4	SARG|gi|686251508|ref|WP_031837026.1|	21.5	432	452	451	6.32e-15	75.5
k141_176640_4	SARG|gi|446573710|ref|WP_000651056.1|	22.0	432	452	451	6.32e-15	75.5
k141_176640_4	SARG|gi|487138435|ref|WP_001629863.1|	22.0	432	452	451	6.32e-15	75.5
k141_119700_4	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	27.8	205	575	505	2.46e-16	80.9
k141_119700_4	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	27.8	205	575	504	7.60e-16	79.3
k141_119700_4	SARG|gi|727023243|ref|WP_033594420.1|	21.9	233	575	498	4.98e-09	57.8
k141_119700_4	SARG|gi|488297611|ref|WP_002368819.1|	21.5	233	575	498	8.70e-09	57.0
k141_119700_4	SARG|ZP_04437889	21.5	233	575	498	8.70e-09	57.0
k141_119700_4	SARG|ZP_03984253	21.5	233	575	498	8.70e-09	57.0
k141_119700_4	SARG|ZP_04646474	21.5	233	575	498	8.70e-09	57.0
k141_119700_4	SARG|gi|895824744|ref|WP_048947239.1|	21.5	233	575	499	8.72e-09	57.0
k141_119700_4	SARG|gi|498399452|ref|WP_010712758.1|	21.9	233	575	498	1.15e-08	56.6
k141_119700_4	SARG|gi|895818174|ref|WP_048942695.1|	21.5	233	575	498	1.52e-08	56.2
k141_116096_1	SARG|gb|ABX00624.1|ARO:3002881|lmrC	37.9	103	257	550	6.14e-13	67.0
k141_116096_1	SARG|gb|QQA64075.1|ARO:3007043|msr(I)	38.8	85	257	485	2.76e-11	62.0
k141_116096_1	SARG|AAZ32816	38.0	100	257	488	6.74e-11	60.8
k141_116096_1	SARG|ABA02367	38.0	100	257	488	6.74e-11	60.8
k141_116096_1	SARG|gi|127359|sp|P23212.1|MSRA_STAEP	38.0	100	257	488	6.74e-11	60.8
k141_116096_1	SARG|BAD86537	38.9	90	257	488	1.64e-10	59.7
k141_116096_1	SARG|gi|581672381|gb|EVQ77821.1|	38.9	90	257	394	1.94e-10	59.3
k141_116096_1	SARG|gi|587321226|gb|EWW03298.1|	38.9	90	257	413	2.00e-10	59.3
k141_116096_1	SARG|gi|580336413|gb|EVD62957.1|	38.9	90	257	478	2.18e-10	59.3
k141_116096_1	SARG|gb|QHW12375.1|ARO:3005087|msrF	40.2	82	257	486	2.20e-10	59.3
k141_66699_1	SARG|gb|WP_104671188.1|ARO:3003948|efrA	45.2	462	469	575	1.24e-128	384
k141_66699_1	SARG|gb|AAK76137.1|ARO:3000024|patA	36.3	454	469	564	2.19e-94	295
k141_66699_1	SARG|gi|930482089|ref|WP_054228897.1|	34.6	367	469	599	3.21e-62	211
k141_66699_1	SARG|gi|985844137|ref|WP_060895163.1|	34.6	367	469	599	3.21e-62	211
k141_66699_1	SARG|gi|655401130|ref|WP_028800283.1|	34.7	372	469	599	3.26e-61	209
k141_66699_1	SARG|gi|748767925|ref|WP_040019608.1|	34.1	372	469	623	3.61e-60	206
k141_66699_1	SARG|gi|655413091|ref|WP_028811890.1|	34.9	372	469	603	1.85e-59	204
k141_66699_1	SARG|gi|1011969930|ref|WP_062776015.1|	34.1	372	469	601	2.48e-59	204
k141_66699_1	SARG|gi|664244930|ref|WP_030776974.1|	33.6	372	469	601	3.45e-59	203
k141_66699_1	SARG|gi|943938624|ref|WP_055567802.1|	33.9	372	469	602	3.51e-59	203
k141_66699_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	52.7	332	604	362	4.55e-111	336
k141_66699_2	SARG|gb|AAK76136.1|ARO:3000025|patB	35.0	575	604	588	8.71e-108	335
k141_66699_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	36.2	481	604	664	4.05e-95	304
k141_66699_2	SARG|gi|497748188|ref|WP_010062372.1|	32.0	597	604	605	2.89e-88	285
k141_66699_2	SARG|gi|764446018|ref|WP_044369325.1|	32.0	587	604	605	6.01e-87	281
k141_66699_2	SARG|gi|695865802|ref|WP_032778631.1|	32.0	587	604	605	6.01e-87	281
k141_66699_2	SARG|gi|951183771|ref|WP_057661487.1|	32.2	587	604	603	8.02e-87	281
k141_66699_2	SARG|gi|695887424|ref|WP_032788534.1|	32.2	581	604	605	8.42e-87	281
k141_66699_2	SARG|gi|1045390184|ref|WP_065479071.1|	32.0	581	604	605	1.65e-86	280
k141_66699_2	SARG|gi|664180077|ref|WP_030714054.1|	32.0	581	604	605	1.65e-86	280
k141_119716_8	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	35.9	223	333	255	3.88e-42	145
k141_119716_8	SARG|YP_001571041	37.0	227	333	648	2.98e-38	142
k141_119716_8	SARG|gi|960873409|ref|WP_058345546.1|	37.0	227	333	648	2.98e-38	142
k141_119716_8	SARG|gi|446048013|ref|WP_000125868.1|	37.6	234	333	648	4.08e-38	142
k141_119716_8	SARG|gi|740610794|ref|WP_038396317.1|	37.0	227	333	648	7.65e-38	141
k141_119716_8	SARG|gi|555268037|ref|WP_023249477.1|	37.6	221	333	648	1.96e-37	140
k141_119716_8	SARG|gi|924626178|ref|WP_053530123.1|	37.6	221	333	648	2.69e-37	140
k141_119716_8	SARG|gi|924503108|ref|WP_053510027.1|	37.1	221	333	648	9.41e-37	138
k141_119716_8	SARG|gi|974672242|ref|WP_059256507.1|	37.6	221	333	648	2.92e-35	134
k141_119716_8	SARG|gi|974641719|ref|WP_059227752.1|	37.6	221	333	648	2.92e-35	134
k141_32100_1	NCBI|WP_070509550.1|1|1|mef(H)|mef(H)|efflux|2|ERYTHROMYCIN|MACROLIDE|macrolide_efflux_MFS_transporter_Mef(H)|AMR|macrolide	32.2	149	155	412	5.21e-16	72.8
k141_32100_1	SARG|gb|QQM99829.1|ARO:3007047|mefH	33.7	95	155	109	4.82e-12	58.2
k141_32100_2	SARG|gi|446026113|ref|WP_000103968.1|	32.8	201	351	306	5.70e-29	112
k141_32100_2	SARG|gi|507044560|ref|WP_016115614.1|	32.3	201	351	306	2.10e-28	111
k141_32100_2	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	26.0	262	351	307	7.04e-25	101
k141_32100_2	SARG|gi|895865878|ref|WP_048974758.1|	34.5	206	351	646	1.48e-22	97.8
k141_32100_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	25.2	214	351	664	7.17e-13	68.6
k141_32100_2	SARG|gb|AAK76136.1|ARO:3000025|patB	25.9	228	351	588	2.13e-12	67.0
k141_32100_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	25.1	191	351	362	6.03e-09	55.8
k141_20967_7	SARG|gi|823291602|ref|WP_047047573.1|	43.7	222	249	648	4.43e-49	169
k141_20967_7	SARG|gi|1022688710|ref|WP_063443532.1|	43.7	222	249	648	1.18e-48	168
k141_20967_7	SARG|gi|895981299|ref|WP_049056431.1|	43.2	222	249	648	1.63e-48	168
k141_20967_7	SARG|gi|823281237|ref|WP_047037467.1|	43.2	222	249	648	1.63e-48	168
k141_20967_7	SARG|gi|895967513|ref|WP_049046752.1|	43.2	222	249	648	1.63e-48	168
k141_20967_7	SARG|gi|779903733|ref|WP_045374054.1|	43.2	222	249	648	1.63e-48	168
k141_20967_7	SARG|gi|823326845|ref|WP_047080664.1|	43.2	222	249	648	3.13e-48	167
k141_20967_7	SARG|gi|695793471|ref|WP_032707680.1|	43.2	222	249	648	3.13e-48	167
k141_20967_7	SARG|gi|823302270|ref|WP_047057473.1|	43.2	222	249	648	4.34e-48	167
k141_20967_7	SARG|gi|976146774|ref|WP_059305359.1|	43.2	222	249	648	4.34e-48	167
k141_24537_5	NCBI|WP_046930149.1|1|1|aac(6')_Strep|aac(6')_Strep|acetyltransferase|2|aminoglycoside|aminoglycoside|aminoglycoside_6'-N-acetyltransferase|AMR|aminoglycoside	30.2	172	180	157	2.21e-12	60.8
k141_24537_5	NCBI|WP_046502149.1|1|1|aac(6')_Strep|aac(6')_Strep|acetyltransferase|2|aminoglycoside|aminoglycoside|aminoglycoside_6'-N-acetyltransferase|AMR|aminoglycoside	35.5	107	180	157	8.36e-10	53.9
k141_138742_2	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	29.8	171	268	314	1.22e-13	68.6
k141_134798_2	CARD|gb|AAD51347.1|ARO:3003067|smeS	28.8	306	479	467	2.10e-35	136
k141_134798_2	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.4	277	479	370	5.71e-31	122
k141_134798_2	CARD|gb|ABD30512.1|ARO:3000839|arlS	28.4	299	479	451	1.82e-30	122
k141_134798_2	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	25.5	290	479	365	1.23e-29	118
k141_134798_2	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	28.2	252	479	357	3.95e-21	93.6
k141_134798_2	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	28.2	252	479	357	3.95e-21	93.6
k141_134798_2	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	25.6	215	479	380	1.34e-19	89.4
k141_134798_2	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.6	215	479	380	1.34e-19	89.4
k141_134798_2	CARD|gb|AEX49906.1|ARO:3003583|basS	23.9	284	479	477	2.57e-19	89.4
k141_134798_3	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	45.9	222	230	228	1.79e-63	196
k141_134798_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.3	230	230	231	2.56e-61	191
k141_134798_3	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	44.9	227	230	232	2.64e-61	191
k141_134798_3	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	44.9	227	230	232	2.64e-61	191
k141_134798_3	CARD|gb|ATC67679.1|ARO:3000838|arlR	42.5	219	230	219	7.12e-61	189
k141_134798_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.7	230	230	232	7.50e-61	189
k141_134798_3	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	43.3	233	230	235	7.54e-59	184
k141_134798_3	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	41.1	231	230	232	4.45e-57	180
k141_134798_3	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	43.2	236	230	239	5.49e-57	180
k141_134798_3	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	41.6	231	230	233	9.19e-57	179
k141_82228_2	SARG|gb|APB03216.1|ARO:3003982|LlmA	53.7	287	288	287	3.60e-119	342
k141_82228_3	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	34.1	229	281	343	1.69e-32	121
k141_82228_3	SARG|gi|671541568|ref|WP_031525212.1|	35.1	228	281	648	7.63e-31	120
k141_82228_3	SARG|gi|446048013|ref|WP_000125868.1|	32.6	221	281	648	3.59e-28	112
k141_82228_3	SARG|gi|953808775|ref|WP_058042812.1|	32.8	241	281	608	7.02e-25	102
k141_82228_3	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	25.7	210	281	528	1.18e-12	66.6
k141_82228_3	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	24.9	209	281	655	2.65e-09	56.6
k141_82228_3	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	24.9	209	281	655	4.74e-09	55.8
k141_82228_3	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	24.9	209	281	655	4.74e-09	55.8
k141_82228_3	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	24.9	209	281	655	4.74e-09	55.8
k141_82228_3	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	24.9	209	281	655	4.74e-09	55.8
k141_82228_4	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	33.5	227	292	255	1.81e-33	122
k141_82228_4	SARG|gb|AAK76137.1|ARO:3000024|patA	30.6	222	292	564	3.78e-24	100
k141_82228_4	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	29.9	251	292	579	2.03e-22	95.9
k141_82228_4	SARG|gb|WP_104671188.1|ARO:3003948|efrA	31.7	202	292	575	1.13e-19	87.8
k141_82228_4	SARG|gi|926286457|ref|WP_053623344.1|	30.6	216	292	605	5.24e-19	85.9
k141_82228_4	SARG|gi|664317010|ref|WP_030845774.1|	30.6	216	292	605	9.55e-19	85.1
k141_82228_4	SARG|gi|663286402|ref|WP_030292859.1|	30.6	216	292	605	9.55e-19	85.1
k141_82228_4	SARG|gi|663342223|ref|WP_030341347.1|	30.6	216	292	605	9.55e-19	85.1
k141_82228_4	SARG|gi|759527374|ref|WP_043247487.1|	30.6	216	292	605	9.55e-19	85.1
k141_82228_4	SARG|gi|1045390184|ref|WP_065479071.1|	28.8	236	292	605	9.55e-19	85.1
k141_47610_2	SARG|ZP_04433866	59.7	278	287	288	5.01e-107	311
k141_47610_2	SARG|ZP_03949893	59.7	278	287	288	5.01e-107	311
k141_47610_2	SARG|ZP_03984017	59.4	278	287	288	1.01e-106	310
k141_47610_2	SARG|YP_002929946	54.2	288	287	282	4.19e-97	286
k141_47610_2	SARG|ZP_04528247	56.0	277	287	279	1.53e-96	284
k141_47610_2	SARG|ZP_03958019	51.4	280	287	317	2.97e-90	270
k141_47610_2	SARG|ZP_03938934	53.2	278	287	288	3.33e-90	268
k141_47610_2	SARG|ZP_03941859	53.2	278	287	288	4.72e-90	268
k141_47610_2	SARG|YP_002937728	51.9	285	287	289	2.79e-89	266
k141_47610_2	SARG|ZP_03945515	51.2	283	287	291	1.57e-86	259
k141_47610_5	CARD|gb|AAD51347.1|ARO:3003067|smeS	31.5	298	484	467	6.43e-33	129
k141_47610_5	CARD|gb|ABD30512.1|ARO:3000839|arlS	28.2	298	484	451	2.21e-31	124
k141_47610_5	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.4	241	484	381	7.72e-20	90.1
k141_47610_5	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.4	241	484	381	7.72e-20	90.1
k141_47610_5	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	25.8	252	484	392	9.03e-19	87.0
k141_47610_5	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.4	242	484	381	1.11e-18	86.7
k141_47610_5	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.4	242	484	381	1.11e-18	86.7
k141_47610_5	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.4	242	484	381	3.59e-18	85.1
k141_47610_5	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.4	242	484	381	3.59e-18	85.1
k141_47610_5	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	24.6	232	484	370	1.49e-16	80.1
k141_47610_6	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	39.1	235	231	252	1.19e-41	141
k141_47610_6	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.6	229	231	232	3.89e-41	139
k141_47610_6	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.2	224	231	228	1.38e-40	137
k141_47610_6	CARD|gb|AAD51348.1|ARO:3003066|smeR	38.6	223	231	229	4.43e-39	134
k141_47610_6	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.1	228	231	231	4.46e-36	126
k141_47610_6	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	33.2	226	231	225	9.15e-34	120
k141_47610_6	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	34.5	229	231	232	4.27e-33	118
k141_47610_6	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	34.5	229	231	232	4.27e-33	118
k141_47610_6	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	35.4	206	231	225	3.92e-32	115
k141_47610_6	CARD|gb|AAC73788.1|ARO:3003841|kdpE	35.4	206	231	225	3.92e-32	115
k141_47610_12	SARG|gi|505420018|ref|WP_015607120.1|	30.5	220	251	603	9.78e-24	98.6
k141_47610_12	SARG|gi|817122037|ref|WP_046494699.1|	31.9	235	251	613	3.36e-23	97.1
k141_47610_12	SARG|gi|947982677|ref|WP_056642336.1|	29.6	223	251	626	4.61e-23	96.7
k141_47610_12	SARG|gi|639892676|ref|WP_024755698.1|	29.6	223	251	631	4.63e-23	96.7
k141_47610_12	SARG|gi|739906046|ref|WP_037756452.1|	30.4	237	251	620	6.23e-23	96.3
k141_47610_12	SARG|gi|944152509|ref|WP_055644808.1|	29.6	223	251	616	8.41e-23	95.9
k141_47610_12	SARG|gi|516574297|ref|WP_017949361.1|	30.4	237	251	620	1.15e-22	95.5
k141_47610_12	SARG|gi|496018010|ref|WP_008742581.1|	30.0	243	251	623	1.15e-22	95.5
k141_47610_12	SARG|gi|695842130|ref|WP_032755430.1|	30.1	216	251	603	1.53e-22	95.1
k141_47610_12	SARG|gi|558888514|ref|WP_023543283.1|	30.1	239	251	615	2.85e-22	94.4
k141_47610_15	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.5	117	639	232	6.08e-10	58.9
k141_47610_15	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	28.3	127	639	231	1.09e-09	58.2
k141_47610_15	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	24.8	141	639	231	2.87e-08	53.9
k141_47610_15	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	26.5	113	639	219	4.50e-08	53.1
k141_47610_15	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	26.5	113	639	219	4.50e-08	53.1
k141_47610_15	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	26.5	113	639	220	4.56e-08	53.1
k141_47610_15	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	26.5	113	639	220	6.14e-08	52.8
k141_47610_15	CARD|gb|ADM92605.1|ARO:3000553|adeR	29.7	118	639	247	1.10e-07	52.4
k141_47610_15	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	26.5	113	639	220	1.11e-07	52.0
k141_158038_4	SARG|HE999704.1.gene3064.p01	30.8	143	452	241	2.37e-13	68.6
k141_158038_4	SARG|gi|441475675|emb|CCQ25429.1|	35.3	85	452	211	2.58e-08	53.1
k141_47667_13	SARG|gi|447195835|ref|WP_001273091.1|	26.1	188	634	306	3.42e-14	72.8
k141_47667_13	SARG|gi|447195836|ref|WP_001273092.1|	25.5	188	634	306	8.28e-14	71.6
k141_47667_13	SARG|gi|736993687|ref|WP_034989673.1|	34.7	121	634	513	4.15e-08	55.1
k141_47667_13	SARG|AF024666.2.gene6.p01	34.7	121	634	513	4.15e-08	55.1
k141_47667_13	SARG|gi|171851258|emb|CAQ04234.1|	31.0	142	634	483	6.92e-08	54.3
k141_47667_13	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	25.8	194	634	568	5.32e-07	51.6
k141_47667_13	SARG|gi|686436876|ref|WP_031922735.1|	25.4	193	634	491	6.45e-07	51.2
k141_47667_13	megares|MEG_4068|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|MSRA_1	24.4	193	634	176	1.66e-06	47.8
k141_47667_13	SARG|gi|686444151|ref|WP_031925491.1|	25.4	193	634	488	1.95e-06	49.7
k141_47667_13	SARG|gi|581672381|gb|EVQ77821.1|	24.9	193	634	394	2.20e-06	49.3
k141_134908_7	CARD|gb|AAC75429.1|ARO:3000833|evgS	31.8	330	662	1197	1.06e-37	149
k141_134908_7	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.0	246	662	381	5.11e-17	82.4
k141_134908_7	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.0	246	662	381	5.11e-17	82.4
k141_134908_7	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.3	247	662	381	2.18e-16	80.5
k141_134908_7	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.3	247	662	381	2.18e-16	80.5
k141_134908_7	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.8	248	662	381	3.89e-16	79.7
k141_134908_7	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.8	248	662	381	3.89e-16	79.7
k141_134908_7	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.9	247	662	381	5.20e-16	79.3
k141_134908_7	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.9	247	662	381	5.20e-16	79.3
k141_134908_7	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.9	249	662	381	3.93e-14	73.6
k141_40154_8	SARG|gi|851901342|ref|WP_048211771.1|	25.1	414	444	457	4.50e-18	85.1
k141_40154_8	SARG|gi|780027477|ref|WP_045442423.1|	24.1	410	444	457	8.05e-18	84.3
k141_40154_8	SARG|gi|491269060|ref|WP_005127195.1|	24.9	414	444	457	1.44e-17	83.6
k141_40154_8	SARG|gi|1002398650|ref|WP_061381408.1|	24.6	414	444	457	1.44e-17	83.6
k141_40154_8	SARG|gi|754952496|ref|WP_042308660.1|	24.6	414	444	457	1.92e-17	83.2
k141_40154_8	SARG|gi|489929427|ref|WP_003832751.1|	24.9	414	444	457	1.92e-17	83.2
k141_40154_8	SARG|gi|851915138|ref|WP_048216502.1|	24.9	414	444	457	6.13e-17	81.6
k141_40154_8	SARG|gi|851908704|ref|WP_048214273.1|	24.6	414	444	457	1.09e-16	80.9
k141_40154_8	SARG|YP_002849300	24.6	414	444	457	1.95e-16	80.1
k141_40154_8	SARG|gi|757799242|ref|WP_043016444.1|	24.9	414	444	457	1.95e-16	80.1
k141_40154_10	SARG|gi|446048013|ref|WP_000125868.1|	29.9	201	419	648	1.69e-21	95.9
k141_134938_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	43.2	146	144	232	5.08e-34	117
k141_134938_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	42.6	141	144	228	1.14e-31	111
k141_134938_1	CARD|gb|ATC67679.1|ARO:3000838|arlR	44.5	137	144	219	2.87e-30	107
k141_134938_1	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	39.3	145	144	229	3.64e-30	107
k141_134938_1	CARD|gb|AAG05188.1|ARO:3005068|ParR	42.8	145	144	235	1.17e-29	106
k141_134938_1	CARD|gb|AAD51348.1|ARO:3003066|smeR	43.4	143	144	229	2.02e-29	105
k141_134938_1	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	40.0	120	144	225	1.87e-21	85.1
k141_134938_1	CARD|gb|ADM92605.1|ARO:3000553|adeR	34.5	145	144	247	7.60e-21	84.0
k141_134938_1	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	32.5	154	144	252	4.58e-19	79.3
k141_134938_2	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.6	283	503	370	8.19e-29	116
k141_134938_2	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	25.4	279	503	365	1.07e-24	104
k141_146345_3	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	32.0	250	441	356	1.50e-19	88.6
k141_146345_3	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	33.3	225	441	346	2.73e-18	84.7
k141_146345_3	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	32.4	250	441	355	4.02e-18	84.3
k141_146345_3	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	32.4	250	441	355	4.02e-18	84.3
k141_146345_3	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	32.0	250	441	355	4.02e-18	84.3
k141_146345_3	SARG|BAE96115	32.0	250	441	355	4.02e-18	84.3
k141_146345_3	SARG|ACM47285	32.4	250	441	363	4.32e-18	84.3
k141_146345_3	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.9	269	441	356	7.36e-18	83.6
k141_146345_3	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	31.2	250	441	356	3.25e-17	81.6
k141_146345_3	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	33.0	182	441	209	1.37e-13	68.6
k141_17683_1	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	36.5	222	235	225	2.87e-40	137
k141_17683_1	CARD|gb|AAC73788.1|ARO:3003841|kdpE	36.5	222	235	225	2.87e-40	137
k141_17683_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	34.5	229	235	232	5.99e-38	131
k141_17683_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	34.5	229	235	232	5.99e-38	131
k141_17683_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	34.8	230	235	231	3.92e-35	124
k141_17683_1	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	33.3	231	235	231	6.03e-34	120
k141_17683_1	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.3	231	235	231	6.03e-34	120
k141_17683_1	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.8	231	235	231	2.36e-33	119
k141_17683_1	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	31.2	231	235	231	4.67e-33	118
k141_17683_1	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	32.9	228	235	231	1.30e-32	117
k141_78368_3	SARG|NP_348076	28.4	395	610	652	3.61e-30	124
k141_78368_3	SARG|ZP_02632674	25.8	400	610	660	1.19e-29	123
k141_78368_3	SARG|YP_002850805	26.7	393	610	652	3.65e-29	121
k141_78368_3	SARG|L20800.gene.p01	26.0	393	610	652	4.87e-29	121
k141_78368_3	SARG|ZP_02952732	26.0	393	610	652	6.50e-29	120
k141_78368_3	SARG|BAD46890	40.8	147	610	657	4.95e-28	118
k141_78368_3	SARG|AAZ79478	40.8	147	610	657	6.60e-28	117
k141_78368_3	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	40.8	147	610	657	6.60e-28	117
k141_78368_3	SARG|Z21523.gene.p01	40.8	147	610	657	6.60e-28	117
k141_78368_3	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	40.8	147	610	670	6.88e-28	117
k141_36648_1	SARG|gi|446048013|ref|WP_000125868.1|	27.4	223	424	648	1.25e-23	102
k141_36648_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.8	228	424	664	1.03e-14	75.1
k141_36648_1	SARG|gi|835330218|ref|WP_047457825.1|	28.8	104	424	648	1.37e-08	55.8
k141_36648_1	SARG|YP_001453760	28.8	104	424	648	1.37e-08	55.8
k141_36648_1	SARG|gi|754964360|ref|WP_042320280.1|	24.2	161	424	648	3.16e-08	54.7
k141_36648_1	SARG|gi|754927849|ref|WP_042284850.1|	24.8	161	424	648	3.16e-08	54.7
k141_36648_1	SARG|gi|757782629|ref|WP_043001213.1|	27.9	104	424	648	5.53e-08	53.9
k141_36648_1	SARG|gi|817104523|ref|WP_046477871.1|	27.9	104	424	648	5.53e-08	53.9
k141_36648_1	SARG|gi|992390012|ref|WP_061077002.1|	27.9	104	424	648	5.53e-08	53.9
k141_36648_1	SARG|gi|763407609|ref|WP_044264203.1|	27.9	104	424	648	5.53e-08	53.9
k141_3307_4	SARG|gi|554922094|ref|WP_023194682.1|	42.7	239	260	648	4.41e-59	197
k141_3307_4	SARG|gi|923061916|ref|WP_053445667.1|	42.3	239	260	648	6.15e-59	196
k141_3307_4	SARG|YP_002044935	42.3	239	260	648	1.20e-58	196
k141_3307_4	SARG|gi|835666879|ref|WP_047606339.1|	42.3	239	260	648	1.20e-58	196
k141_3307_4	SARG|gi|922019548|ref|WP_053299973.1|	42.3	239	260	648	1.20e-58	196
k141_3307_4	SARG|gi|555254264|ref|WP_023237471.1|	42.3	239	260	648	1.20e-58	196
k141_3307_4	SARG|gi|959101689|ref|WP_058107049.1|	42.3	239	260	648	1.20e-58	196
k141_3307_4	SARG|gi|763399392|ref|WP_044256358.1|	43.6	225	260	648	1.20e-58	196
k141_3307_4	SARG|gi|970558766|ref|WP_058820271.1|	42.3	239	260	648	1.67e-58	195
k141_3307_4	SARG|Q57R58	42.7	239	260	648	1.67e-58	195
k141_36699_11	SARG|gb|XP_753111.1|ARO:3003942|abcA	26.6	233	506	1452	4.44e-06	48.5
k141_67459_1	SARG|gb|AAC75089.1|ARO:3003577|ugd	65.8	284	286	388	7.39e-125	360
k141_85893_14	NCBI|WP_032488596.1|1|1|nimA|nimA|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimA|AMR|nitroimidazole	46.4	153	159	176	9.21e-41	134
k141_85893_14	megares|MEG_4190|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMI_1	44.8	154	159	152	1.49e-39	130
k141_85893_14	megares|MEG_4193|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMI_1	44.2	154	159	152	1.49e-39	130
k141_85893_14	ResF|nimI_1_FJ940884_1	44.3	158	159	165	1.53e-39	130
k141_85893_14	ResF|nimI_1_FJ940887_1	43.7	158	159	165	1.53e-39	130
k141_85893_14	NCBI|WP_087312253.1|1|1|nimG|nimG||2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimG|AMR|nitroimidazole	44.4	153	159	164	2.11e-39	130
k141_85893_14	megares|MEG_4191|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMI_1	44.2	154	159	152	2.98e-39	129
k141_85893_14	ResF|nimI_1_FJ940886_1	43.7	158	159	165	3.08e-39	129
k141_85893_14	ResF|nimI_1_FJ940889_1	43.7	158	159	165	3.08e-39	129
k141_85893_14	megares|MEG_4192|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMI_1	44.2	154	159	154	4.48e-39	129
k141_10107_3	SARG|gi|497748188|ref|WP_010062372.1|	50.8	238	273	605	2.71e-75	239
k141_10107_3	SARG|gi|764446018|ref|WP_044369325.1|	50.4	238	273	605	1.48e-74	237
k141_10107_3	SARG|gi|695887424|ref|WP_032788534.1|	50.4	238	273	605	2.08e-74	237
k141_10107_3	SARG|gi|664180077|ref|WP_030714054.1|	50.4	238	273	605	2.08e-74	237
k141_10107_3	SARG|gi|1045390184|ref|WP_065479071.1|	50.4	238	273	605	2.92e-74	236
k141_10107_3	SARG|gi|695865802|ref|WP_032778631.1|	50.0	238	273	605	8.09e-74	235
k141_10107_3	SARG|gi|748767925|ref|WP_040019608.1|	50.8	238	273	623	1.64e-73	235
k141_10107_3	SARG|gi|951183771|ref|WP_057661487.1|	49.6	238	273	603	3.02e-73	234
k141_10107_3	SARG|gi|827013130|ref|WP_047175495.1|	50.4	238	273	603	3.02e-73	234
k141_10107_3	SARG|gi|663350985|ref|WP_030349761.1|	50.6	237	273	613	3.70e-73	234
k141_112641_6	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	31.7	394	410	1024	1.21e-55	196
k141_112641_6	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	31.7	394	410	1024	1.21e-55	196
k141_112641_6	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	31.7	394	410	1024	1.21e-55	196
k141_112641_6	SARG|gb|CAA53189|ARO:3000521|mupA	31.7	394	410	1024	1.21e-55	196
k141_112641_6	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	28.6	398	410	1033	1.01e-46	171
k141_112641_6	SARG|gb|AEY83581|ARO:3000510|mupB	28.6	398	410	1033	1.01e-46	171
k141_151054_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	26.1	115	408	228	9.49e-07	48.5
k141_59757_3	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	53.9	1259	1275	1162	0.0	1226
k141_59757_3	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	51.8	1257	1275	1186	0.0	1160
k141_59757_3	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	51.8	1257	1275	1186	0.0	1160
k141_181165_8	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	25.7	222	330	574	1.47e-16	79.3
k141_181165_8	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	23.7	245	330	550	5.35e-11	62.4
k141_181165_9	SARG|gi|751930065|ref|WP_041144773.1|	34.6	231	334	648	1.11e-25	106
k141_181165_9	SARG|gi|749639729|ref|WP_040241690.1|	34.6	231	334	646	1.50e-25	106
k141_181165_9	SARG|gi|823326845|ref|WP_047080664.1|	34.2	231	334	648	1.51e-25	106
k141_181165_9	SARG|Q83LR7	34.8	233	334	648	2.75e-25	105
k141_181165_9	SARG|gi|647325472|ref|WP_025760953.1|	34.8	233	334	648	2.75e-25	105
k141_181165_9	SARG|gi|647323678|ref|WP_025760497.1|	34.8	233	334	648	2.75e-25	105
k141_181165_9	SARG|gi|823302270|ref|WP_047057473.1|	34.2	231	334	648	2.75e-25	105
k141_181165_9	SARG|gi|976146774|ref|WP_059305359.1|	34.2	231	334	648	2.75e-25	105
k141_181165_9	SARG|gi|1022664304|ref|WP_063420886.1|	34.2	231	334	648	2.75e-25	105
k141_181165_9	SARG|gi|823309640|ref|WP_047064288.1|	34.2	231	334	648	2.75e-25	105
k141_37021_3	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	24.2	318	839	633	8.61e-10	61.2
k141_37021_4	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	37.5	427	455	451	1.21e-85	268
k141_37021_4	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.2	427	455	481	7.75e-85	267
k141_37021_4	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	36.8	427	455	451	3.20e-82	259
k141_67730_1	SARG|gi|1033064422|ref|WP_064375412.1|	35.7	70	449	648	3.03e-06	48.5
k141_67730_1	SARG|gi|1031824807|ref|WP_064152164.1|	35.7	70	449	646	5.27e-06	47.8
k141_67730_1	SARG|gi|695840638|ref|WP_032753940.1|	35.7	70	449	646	9.18e-06	47.0
k141_67730_1	SARG|gi|823326845|ref|WP_047080664.1|	35.7	70	449	648	9.19e-06	47.0
k141_67730_1	SARG|gi|695793471|ref|WP_032707680.1|	35.7	70	449	648	9.19e-06	47.0
k141_67730_1	SARG|gi|823291602|ref|WP_047047573.1|	35.7	70	449	648	9.19e-06	47.0
k141_67730_1	SARG|gi|823302270|ref|WP_047057473.1|	35.7	70	449	648	9.19e-06	47.0
k141_67730_1	SARG|gi|976146774|ref|WP_059305359.1|	35.7	70	449	648	9.19e-06	47.0
k141_67730_1	SARG|gi|1022664304|ref|WP_063420886.1|	35.7	70	449	648	9.19e-06	47.0
k141_67730_1	SARG|gi|895981299|ref|WP_049056431.1|	35.7	70	449	648	9.19e-06	47.0
k141_124284_1	SARG|P42332	43.6	264	266	306	1.42e-60	192
k141_124284_1	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	43.6	264	266	306	1.42e-60	192
k141_124284_1	SARG|gi|510143239|gb|AGN36970.1|	43.6	264	266	313	1.73e-60	192
k141_124284_1	SARG|AAD21213	43.2	264	266	306	5.66e-60	191
k141_124284_1	SARG|ABB80128	43.2	264	266	306	7.99e-60	191
k141_124284_1	SARG|gi|500465078|gb|EOP76697.1|	51.7	205	266	306	1.59e-59	190
k141_124284_1	SARG|gi|500448961|gb|EOP61695.1|	51.7	205	266	306	2.25e-59	189
k141_124284_1	SARG|gi|487936534|ref|WP_002010000.1|	50.5	208	266	309	1.94e-58	187
k141_124284_1	SARG|gi|446026113|ref|WP_000103968.1|	49.5	208	266	306	2.52e-58	187
k141_124284_1	SARG|gi|507044560|ref|WP_016115614.1|	49.5	208	266	306	2.52e-58	187
k141_154823_1	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	27.9	222	247	293	4.55e-20	85.9
k141_181271_16	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	32.6	236	236	255	1.72e-43	146
k141_181271_16	SARG|gi|803568669|ref|WP_046077412.1|	33.6	226	236	648	2.53e-35	131
k141_181271_16	SARG|gi|446110352|ref|WP_000188207.1|	33.6	226	236	648	2.53e-35	131
k141_181271_16	SARG|YP_002382193	33.6	226	236	648	2.53e-35	131
k141_181271_16	SARG|gi|803575554|ref|WP_046081557.1|	33.6	226	236	648	2.53e-35	131
k141_181271_16	SARG|gi|446110351|ref|WP_000188206.1|	33.6	226	236	648	2.53e-35	131
k141_181271_16	SARG|gi|1035706844|ref|WP_064548272.1|	31.9	238	236	648	2.53e-35	131
k141_181271_16	SARG|gi|736472622|ref|WP_034494292.1|	32.7	226	236	648	4.74e-35	130
k141_181271_16	SARG|gi|1035670474|ref|WP_064517458.1|	32.3	226	236	648	1.67e-34	129
k141_181271_16	SARG|gi|1035717981|ref|WP_064557480.1|	32.3	226	236	648	1.67e-34	129
k141_90690_4	SARG|KF478993.1.gene2.p01	43.5	283	329	350	2.02e-74	232
k141_90690_4	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	42.2	287	329	337	1.96e-71	224
k141_90690_4	SARG|gi|740152780|ref|WP_037997109.1|	39.8	289	329	322	2.24e-69	218
k141_90690_4	SARG|DQ018711.1.gene4.p01	39.9	298	329	322	8.90e-69	216
k141_90690_4	SARG|gi|552942232|ref|WP_023043160.1|	41.5	289	329	323	9.17e-69	216
k141_90690_4	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	41.5	289	329	323	9.17e-69	216
k141_90690_4	SARG|gi|746609237|ref|WP_039635344.1|	40.1	289	329	322	2.51e-68	215
k141_90690_4	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	41.3	271	329	343	3.25e-68	216
k141_90690_4	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	41.3	271	329	348	3.75e-68	216
k141_90690_4	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	39.8	299	329	351	5.75e-68	215
k141_90719_1	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	23.7	270	483	359	3.58e-12	66.6
k141_90719_2	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.5	230	236	231	1.43e-45	150
k141_90719_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	39.5	233	236	231	2.02e-45	150
k141_90719_2	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.5	233	236	231	2.02e-45	150
k141_90719_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.1	231	236	231	5.69e-45	149
k141_90719_2	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.1	230	236	231	8.03e-45	149
k141_90719_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.8	232	236	228	1.04e-44	148
k141_90719_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.0	230	236	232	3.28e-44	147
k141_90719_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.0	230	236	232	3.28e-44	147
k141_90719_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.8	232	236	231	8.98e-44	146
k141_90719_2	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.2	231	236	231	8.98e-44	146
k141_121123_3	ResF|mre(A)_1_U92073_1	28.3	290	307	310	2.02e-21	91.3
k141_121123_3	SARG|gb|AAB64408.1|ARO:3007050|mreA	28.3	290	307	311	2.05e-21	91.3
k141_121146_6	SARG|gb|AAR96051.1|ARO:3002894|otrC	27.3	205	427	351	2.53e-14	72.8
k141_121146_6	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	26.8	205	427	351	1.46e-13	70.5
k141_121146_6	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	25.2	270	427	550	1.87e-10	61.6
k141_33749_1	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	37.2	148	140	255	2.41e-28	103
k141_33749_1	SARG|gi|740610794|ref|WP_038396317.1|	35.1	148	140	648	2.24e-26	102
k141_33749_1	SARG|gi|803568669|ref|WP_046077412.1|	34.5	148	140	648	5.69e-26	100
k141_33749_1	SARG|gi|446110352|ref|WP_000188207.1|	34.5	148	140	648	5.69e-26	100
k141_33749_1	SARG|YP_002382193	34.5	148	140	648	5.69e-26	100
k141_33749_1	SARG|gi|803575554|ref|WP_046081557.1|	34.5	148	140	648	5.69e-26	100
k141_33749_1	SARG|gi|446110351|ref|WP_000188206.1|	34.5	148	140	648	5.69e-26	100
k141_33749_1	SARG|YP_001571041	34.5	148	140	648	7.76e-26	100
k141_33749_1	SARG|gi|960873409|ref|WP_058345546.1|	34.5	148	140	648	7.76e-26	100
k141_33749_1	SARG|gi|495067432|ref|WP_007792257.1|	35.1	148	140	647	1.27e-24	97.1
k141_60162_12	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	42.6	690	661	703	2.44e-166	492
k141_7454_16	SARG|gb|AVI44920.1|ARO:3004470|poxtA	27.8	223	248	542	4.75e-14	70.1
k141_7454_16	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	27.8	223	248	544	4.76e-14	70.1
k141_7454_16	SARG|gb|ABX00624.1|ARO:3002881|lmrC	30.4	227	248	550	9.55e-13	66.2
k141_7454_16	SARG|U82085.gene.p01	25.4	240	248	552	1.40e-11	62.8
k141_7454_16	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.7	188	248	655	3.63e-11	61.6
k141_7454_16	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.7	188	248	655	3.63e-11	61.6
k141_7454_16	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	23.8	214	248	505	4.44e-11	61.2
k141_7454_16	ResF|poxtA-Ef_1_WP094899500.1_1	26.0	227	248	538	6.13e-11	60.8
k141_7454_16	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	26.0	227	248	543	6.16e-11	60.8
k141_7454_16	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	26.0	227	248	543	6.16e-11	60.8
k141_79304_2	SARG|gi|944152509|ref|WP_055644808.1|	33.0	391	575	616	3.53e-47	173
k141_79304_2	SARG|gb|AAK76137.1|ARO:3000024|patA	32.2	239	575	564	3.47e-35	138
k141_79304_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.1	292	575	664	3.19e-34	136
k141_79304_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	21.7	492	575	575	2.12e-32	130
k141_79304_2	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	29.0	193	575	505	1.25e-09	59.7
k141_79304_2	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	28.7	188	575	504	1.07e-07	53.5
k141_79304_2	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	24.2	207	575	552	9.53e-06	47.4
k141_71766_6	SARG|gb|AEA37904.1|ARO:3003112|lsaC	22.2	198	261	492	2.03e-06	47.4
k141_117536_3	SARG|gb|AAS79458.1|ARO:3001302|chrB	36.5	249	272	280	1.37e-33	122
k141_181854_1	ResF|penA_1_AF515059_1	28.5	533	536	581	1.12e-55	195
k141_181854_3	SARG|gb|AAK76137.1|ARO:3000024|patA	36.3	524	586	564	2.09e-103	322
k141_181854_3	SARG|gb|WP_104671188.1|ARO:3003948|efrA	34.8	546	586	575	1.00e-95	303
k141_181854_3	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.3	492	586	664	6.35e-67	229
k141_181854_3	SARG|gi|516574297|ref|WP_017949361.1|	30.4	542	586	620	1.04e-66	227
k141_181854_3	SARG|gi|739906046|ref|WP_037756452.1|	30.6	543	586	620	2.00e-66	226
k141_181854_3	SARG|gi|948137056|ref|WP_056795395.1|	31.0	542	586	602	1.97e-65	223
k141_181854_3	SARG|gi|664042835|ref|WP_030582300.1|	29.7	538	586	604	2.84e-64	220
k141_181854_3	SARG|gi|1045390184|ref|WP_065479071.1|	29.6	538	586	605	5.59e-64	219
k141_181854_3	SARG|gi|493394434|ref|WP_006350564.1|	29.4	545	586	602	1.41e-63	218
k141_181854_3	SARG|gi|648667297|ref|WP_026359044.1|	30.3	542	586	605	2.08e-63	218
k141_181854_4	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.6	114	147	579	5.72e-13	63.9
k141_181854_4	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	30.7	114	147	579	1.44e-12	62.8
k141_113580_1	SARG|gi|507079934|ref|WP_016150692.1|	36.4	184	185	660	7.68e-31	116
k141_113580_1	SARG|gi|851935911|ref|WP_048224705.1|	36.4	184	185	660	7.68e-31	116
k141_113580_1	SARG|gi|851917461|ref|WP_048217311.1|	36.4	184	185	660	7.68e-31	116
k141_113580_1	SARG|gi|507086291|ref|WP_016157032.1|	36.4	184	185	660	7.68e-31	116
k141_113580_1	SARG|gi|489117806|ref|WP_003027650.1|	36.4	184	185	660	7.68e-31	116
k141_113580_1	SARG|gi|765458296|ref|WP_044714032.1|	36.4	184	185	660	7.68e-31	116
k141_113580_1	SARG|gi|696375142|ref|WP_032949690.1|	36.4	184	185	660	7.68e-31	116
k141_113580_1	SARG|gi|851981245|ref|WP_048240645.1|	36.4	184	185	660	7.68e-31	116
k141_113580_1	SARG|gi|507083067|ref|WP_016153816.1|	36.4	184	185	660	1.05e-30	116
k141_113580_1	SARG|gi|757799830|ref|WP_043017032.1|	36.4	184	185	660	1.05e-30	116
k141_159501_10	SARG|gi|446048013|ref|WP_000125868.1|	27.3	227	233	648	1.58e-21	91.7
k141_159501_11	SARG|AXF35727.1	22.5	200	264	497	5.01e-06	46.2
k141_56908_3	SARG|gb|AJP77054|ARO:3003716|CPS-1	28.1	128	202	290	6.58e-08	50.4
k141_56908_3	SARG|gb|WP_122630825.1|ARO:3006873|EAM-1	27.7	141	202	318	4.30e-07	48.1
k141_56908_3	SARG|gb|AJP77059|ARO:3003670|PEDO-1	27.1	140	202	286	7.27e-07	47.4
k141_56908_3	SARG|EU408351.1.gene26.p01	27.0	126	202	293	1.00e-06	47.0
k141_56908_3	SARG|gb|WP_041884311.1|ARO:3006972|PLN-1	27.0	126	202	289	3.29e-06	45.4
k141_34076_2	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	35.3	521	628	579	7.79e-98	310
k141_34076_2	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	34.1	581	628	579	6.43e-96	305
k141_34076_2	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	33.2	581	628	578	2.57e-83	271
k141_34076_2	SARG|gi|496018010|ref|WP_008742581.1|	30.3	575	628	623	1.87e-74	249
k141_34076_2	SARG|gb|AAC74000.1|ARO:3003950|msbA	29.4	520	628	582	3.99e-74	247
k141_34076_2	SARG|gi|948137056|ref|WP_056795395.1|	30.6	582	628	602	8.68e-74	247
k141_34076_2	SARG|gi|926351744|ref|WP_053683383.1|	29.9	575	628	648	2.29e-73	247
k141_34076_2	SARG|gi|917203192|ref|WP_051809904.1|	30.1	575	628	620	2.48e-73	246
k141_34076_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	31.5	504	628	575	4.87e-73	244
k141_34076_2	SARG|gi|917166849|ref|WP_051773561.1|	30.1	575	628	620	6.71e-73	245
k141_34076_3	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	32.3	505	595	574	6.40e-80	261
k141_34076_3	SARG|gb|WP_104671188.1|ARO:3003948|efrA	30.7	511	595	575	5.37e-77	254
k141_34076_3	SARG|gb|AAK76137.1|ARO:3000024|patA	31.4	510	595	564	9.43e-73	242
k141_34076_3	SARG|gb|AAC74000.1|ARO:3003950|msbA	27.6	500	595	582	4.18e-68	230
k141_34076_3	SARG|gi|664556405|ref|WP_031071225.1|	29.2	487	595	602	6.33e-68	230
k141_34076_3	SARG|gi|1045390184|ref|WP_065479071.1|	29.2	487	595	605	1.81e-67	229
k141_34076_3	SARG|gi|764446018|ref|WP_044369325.1|	29.2	487	595	605	2.53e-66	226
k141_34076_3	SARG|gi|695865802|ref|WP_032778631.1|	29.2	487	595	605	2.53e-66	226
k141_34076_3	SARG|gi|662129758|ref|WP_030081404.1|	29.2	487	595	605	2.53e-66	226
k141_34076_3	SARG|gi|664085850|ref|WP_030624018.1|	29.2	487	595	605	3.52e-66	226
